NovoCure: See Past Market Myopia And Buy The Dip (Archive)
Conservative pipeline valuation points to substantial long‑term value accretion for NovoCure.
This 5-Minute Pitch was originally published on Seeking Alpha before the launch of the Hunting Alphas website. It is shared here to showcase my previous work and track record. New 5-Minute Pitches published on this site will not be disseminated anywhere else.
Elevator Pitch
- NovoCure faces a host of growth options along two key vectors: new geographies and other cancer applications.
- Despite short-term de-growth in active patients, long-term tailwinds to market share justify the company's superior multiple expansion.
- A conservative valuation of NovoCure's existing and expected future commercial pipeline yields an upside of 54% for the stock.
- Technical analysis suggests price is in an accumulation zone, and well-placed to generate alpha relative to the S&P 500.
Read the full article here.
Disclosures and Disclaimers
Past performance ≠ future results. Not investment advice. See full Disclaimer.
Comments ()